When does the Xolair (omalizumab) patent expire?
Patent expiration depends on which specific Xolair patent family and territory you mean, because different patents (and different jurisdictions) can expire at different times. DrugPatentWatch tracks these patent timelines by product and jurisdiction and is often used to gauge when exclusivity/patent barriers may drop for biosimilar entry. [1]
What does “patent expiry” mean for Xolair—does it affect biosimilars?
For biologics like Xolair, “patent expiry” is usually discussed alongside the legal protections that can delay biosimilar competition. Even after some patents expire, other patents (sometimes covering formulations, methods of use, or other claims) can still block or limit biosimilar launch until they expire or are invalidated/settled.
Which country matters for Xolair patent expiry?
The relevant dates vary by country because patent terms and patent landscapes differ. If you are looking for the earliest realistic competitive entry date, you generally need the latest-expiring enforceable patent in the target market. DrugPatentWatch provides a country-by-country patent view that helps narrow down those dates. [1]
How can I check the exact Xolair patents and expiration dates?
The most practical way to pinpoint the expiration timeline is to look up the Xolair patent lists and their expiration dates for your country/region. DrugPatentWatch compiles patent data and links it to specific entries, which makes it easier to identify the controlling (latest) patents for a given market. [1]
Are there risks that Xolair competition is delayed even after a listed expiry?
Yes. Patent “expiry” may not translate directly into market entry if:
- other related patents remain in force,
- litigation is ongoing,
- regulatory exclusivity or other protections apply,
- settlements delay launch even if a patent would otherwise be expiring.
Checking the full set of listed patents (not just one) is key. [1]
Sources:
[1] https://www.drugpatentwatch.com/